The major drawback of current anti-angiogenic therapies is drug resistance, mainly caused by overexpression of the transcription factor, hypoxia-inducible factor 1α (HIF-1α) as a result of treatment-induced hypoxia, which stimulates cancer cells to develop aggressive and immunosuppressive phenotypes. Moreover, the cancer cell resistance to anti-angiogenic therapies is deeply mediated by the communication between tumor cells and tumor-associated macrophages (TAMs)-the most important microenvironmental cells for the coordination of all supportive processes in tumor development. Thus, simultaneous targeting of TAMs and cancer cells could improve the outcome of the anti-angiogenic therapies. Since our previous studies proved that simvastatin (S...
Glioblastoma multiforme (GBM) is one of the deadliest cancers. Temozolomide (TMZ) is the most common...
Treatment strategies for advanced malignancy remain limited in their success, despite major advances...
Die Therapie von metastasierenden Melanomen stellt immer noch eine große Herausforderung dar. Gering...
Abstract Anti-angiogenic therapies for melanoma have not yet been translated into meaningful clinica...
Background: Statins induces cell cycle arrest, apoptosis, reduction of angiogenic factors, inhibitio...
Treatment of melanoma cells by sodium arsenite or statins (simvastatin and lovastatin) dramatically ...
Vascular disrupting agents (VDAs), such as DMXAA, effectively destroy tumor blood vessels and cause ...
Lung cancer is characterized by a high mortality rate probably attributable to early metastasis. Oxi...
Lung cancer is the most common cause of cancer-related death. Nonetheless, a decrease in overall inc...
The HMG-CoA reductase inhibitor simvastatin activates AMP-activated protein kinase (AMPK) and thereb...
Chemoresistance remains a major problem in the treatment of gastric cancer patients. Hence, novel ph...
Despite the approval of several anti-angiogenic therapies for the treatment of cancer patients, clin...
Melanoma is themost lethal formofhumanskincancer.However, only limitedchemotherapy is currentlyavail...
Background: Breast cancer is the most commonly diagnosed cancer worldwide with 2.26 million cases in...
The promise of cancer immunotherapy is that it will not only eradicate primary tumors but will gener...
Glioblastoma multiforme (GBM) is one of the deadliest cancers. Temozolomide (TMZ) is the most common...
Treatment strategies for advanced malignancy remain limited in their success, despite major advances...
Die Therapie von metastasierenden Melanomen stellt immer noch eine große Herausforderung dar. Gering...
Abstract Anti-angiogenic therapies for melanoma have not yet been translated into meaningful clinica...
Background: Statins induces cell cycle arrest, apoptosis, reduction of angiogenic factors, inhibitio...
Treatment of melanoma cells by sodium arsenite or statins (simvastatin and lovastatin) dramatically ...
Vascular disrupting agents (VDAs), such as DMXAA, effectively destroy tumor blood vessels and cause ...
Lung cancer is characterized by a high mortality rate probably attributable to early metastasis. Oxi...
Lung cancer is the most common cause of cancer-related death. Nonetheless, a decrease in overall inc...
The HMG-CoA reductase inhibitor simvastatin activates AMP-activated protein kinase (AMPK) and thereb...
Chemoresistance remains a major problem in the treatment of gastric cancer patients. Hence, novel ph...
Despite the approval of several anti-angiogenic therapies for the treatment of cancer patients, clin...
Melanoma is themost lethal formofhumanskincancer.However, only limitedchemotherapy is currentlyavail...
Background: Breast cancer is the most commonly diagnosed cancer worldwide with 2.26 million cases in...
The promise of cancer immunotherapy is that it will not only eradicate primary tumors but will gener...
Glioblastoma multiforme (GBM) is one of the deadliest cancers. Temozolomide (TMZ) is the most common...
Treatment strategies for advanced malignancy remain limited in their success, despite major advances...
Die Therapie von metastasierenden Melanomen stellt immer noch eine große Herausforderung dar. Gering...